Agilent Technologies, Inc. (NYSE:A) Shares Purchased by Greenleaf Trust

Greenleaf Trust raised its position in Agilent Technologies, Inc. (NYSE:A) by 8.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,810 shares of the medical research company’s stock after purchasing an additional 591 shares during the quarter. Greenleaf Trust’s holdings in Agilent Technologies were worth $1,086,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Agilent Technologies by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock valued at $3,246,209,000 after buying an additional 261,435 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Agilent Technologies by 0.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 11,076,270 shares of the medical research company’s stock valued at $1,238,549,000 after acquiring an additional 39,030 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Agilent Technologies by 17.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,255,526 shares of the medical research company’s stock worth $1,146,773,000 after acquiring an additional 1,519,134 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Agilent Technologies by 2.0% during the 1st quarter. Geode Capital Management LLC now owns 6,203,779 shares of the medical research company’s stock worth $856,310,000 after purchasing an additional 122,329 shares during the period. Finally, Morgan Stanley increased its holdings in Agilent Technologies by 79.4% in the 4th quarter. Morgan Stanley now owns 4,145,767 shares of the medical research company’s stock valued at $620,414,000 after purchasing an additional 1,835,413 shares during the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Agilent Technologies Price Performance

Shares of NYSE A opened at $132.73 on Monday. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. The stock has a market cap of $38.90 billion, a P/E ratio of 31.60, a P/E/G ratio of 4.02 and a beta of 1.11. The stock has a 50 day moving average of $141.18 and a two-hundred day moving average of $129.92. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $151.58.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. Agilent Technologies’s quarterly revenue was down 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.37 EPS. On average, research analysts forecast that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be paid a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.71%. The ex-dividend date is Monday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.38%.

Wall Street Analyst Weigh In

A number of research analysts have commented on A shares. Barclays upped their price target on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Oppenheimer lifted their target price on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Evercore ISI increased their price target on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Stifel Nicolaus raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and raised their price objective for the company from $145.00 to $163.00 in a research note on Friday, April 5th. Finally, Citigroup upped their target price on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $141.29.

Insiders Place Their Bets

In other news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares in the company, valued at $38,086,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Michael R. Mcmullen sold 52,297 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares in the company, valued at $38,086,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $149.00, for a total transaction of $719,372.00. Following the sale, the vice president now directly owns 21,329 shares in the company, valued at approximately $3,178,021. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,610 shares of company stock valued at $9,220,333. 0.33% of the stock is owned by company insiders.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.